Natus wins three-year Novation contract for neoBLUE:
This article was originally published in Clinica
Natus Medical, the San Carlos, California company specialising in medical devices for the paediatric market, has secured a three-year agreement to supply Novation with its neoBLUE LED phototherapy systems, used to treat neonatal jaundice. Irving, Texas-based Novation, in turn, will distribute the devices to US healthcare alliances VHA and University HealthSystem Consortium. The neoBLUE system uses a therapeutic blue LED (light emitting diode) light to degenerate excess bilirubin in jaundiced infants. Healthcare users have said the product provides effective and safe treatment to babies over a shorter period of time, the company claims.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.